Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Day One Biopharmaceuticals, Inc.
CEO
Dr. Jeremy Bender M.B.A., Ph.D.
Employees
169
Industry
Biotechnology
Sector
Healthcare
Market cap
$1B
Company details
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Revenue
CoG
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$8.19M
Cost of goods (CoG)
-$707,000.00
Gross profit (GP)
$7.48M
Operating expense (OE)
-$300.01M
Research and development (R&D)
-$202.83M
General and administrative (G&A)
-$97.19M
Operating income (OI)
-$292.53M
Other income expense (OIE)
-$126.60M
Pretax income (PI)
-$165.93M
Tax (TAX)
-$1.55M
Net income (NI)
-$167.48M
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.40
Margin profit
0.00%
52 week low
$9.68
52 week high
$17.690001
50-day simple moving average
$13.93
200-day simple moving average
$13.98
Percent held by insiders
19.60%
Percent held by institutions
87.02%
Dividend yield
0.00%
